Genentech ( Genentech)

Primary tabs

Genentech's picture

Management

Contact Address

About Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.

Genentech press release, blog etc

Sun, 01/26/2020 - 06:14 Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
Thu, 01/23/2020 - 01:10 Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-Invasive Urothelial Cancer
Wed, 01/22/2020 - 04:36 Genentechs Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy
Wed, 12/11/2019 - 03:27 Genentechs Fixed-dose Subcutaneous Combination of Perjeta and Herceptin Comparable to Intravenous Formulations in People With HER2-Positive Breast Cancer
Tue, 12/10/2019 - 01:31 FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
Sat, 12/07/2019 - 09:29 Genentech Announces New Data on Novel CD20-CD3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas
Tue, 12/03/2019 - 14:50 FDA Approves Genentechs Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sun, 12/01/2019 - 15:39 Positive Phase III Results for Genentechs Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
Sat, 11/23/2019 - 22:46 FDA Grants Priority Review to Genentechs Risdiplam for Spinal Muscular Atrophy
Fri, 11/22/2019 - 11:30 Genentech Presents Pivotal Data Demonstrating Tecentriq in Combination With Avastin Improves Overall Survival in People With the Most Common Form of Liver Cancer
Sat, 11/09/2019 - 23:42 Genentechs Risdiplam Meets Primary Endpoint In Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy
Sat, 11/09/2019 - 16:59 Genentechs Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared To Standard of Care Alone
Tue, 10/29/2019 - 01:09 FDA Accepts Genentechs Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
Sat, 10/19/2019 - 23:38 Genentechs Tecentriq in Combination With Avastin Increased Overall Survival and Progression-Free Survival in People With Unresectable Hepatocellular Carcinoma
Thu, 10/17/2019 - 09:53 Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
Sun, 10/13/2019 - 04:22 Phase III PEMPHIX Study Shows Genentechs Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
Mon, 09/30/2019 - 12:09 Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-Based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
Sun, 09/29/2019 - 05:34 Genentech to Present Results of First Prospective Trial Using Blood-Based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib)
more

InfoBox

HomePagewww.gene.com
Facebookfacebook.com/genentech
Twittertwitter.com/genentech
YouTubeyoutube.com/genentech
Google+plus.google.com/+genentech
Instagraminstagram.com/genentech
Pinterestpinterest.com/genentech
LinkedInus.linkedin.com/company/genentech
Wikipediaen.wikipedia.org/wiki/Genentech